Episode 35. Bispecific Antibodies in Lymphoma with Dr. Michael Dickinson

Blood Cancer Talks

Innehåll tillhandahållet av Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.

10M ago 1:08:40

MP3•Episod hem

In this episode, we delve into the weeds of bispecific antibodies across lymphomas with Dr. Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, Australia. Here are the key articles we discussed:

1. Glofitamab for Relapsed/Refractory DLBCL:

https://pubmed.ncbi.nlm.nih.gov/36507690/

2. Long-term follow-up data on blinatumomab in relapsed/refractory B-cell NHL:

https://pubmed.ncbi.nlm.nih.gov/31451445/

3. Phase 1/2 study of epcoritamab in relapsed/refractory DLBCL:

https://pubmed.ncbi.nlm.nih.gov/36548927/

4. Phase 2 trial of mosunetuzumab in relapsed/refractory follicular lymphoma:

https://pubmed.ncbi.nlm.nih.gov/35803286/

5. Phase 1 trial of odronextamab in relapsed/refractory B-cell NHL:

https://pubmed.ncbi.nlm.nih.gov/35366963/

6. Epcoritamab + R2 in high-risk follicular lymphoma:

https://meetings.asco.org/abstracts-presentations/218265

7. Glofitamab in Mantle Cell Lymphoma:

https://ashpublications.org/blood/article/140/Supplement%201/178/489039

52 episoder

#Fitness #Medicine #Rajshekhar Chakraborty and Ashwin Kishtagari #Ashwin Kishtagari #Rajshekhar Chakraborty #Hematology #Cancer #Podcasting Education #Edward Cliff